Defence Therapeutics Announces Formation of Scientific Advisory Board to Guide Advancement of Accum-Enhanced Antibody Drug Conjugate Programs
Montreal, Quebec--(Newsfile Corp. - December 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, is pleased to announce the formation of its inaugural Scientific Advisory Board ("SAB"), composed of Rob Leanna, Danny Chui, and Brendan Hussey. Defence
Biotechnology, Pharmaceuticals, Health
2025-12-04 3:15 AM EST | Defence Therapeutics Inc.
Hemostemix Featured at Innovations in Wound Healing 2025, Key West, December 11-14
Calgary, Alberta--(Newsfile Corp. - December 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its participation as a premier regenerative medicine company at Innovations in Wound Healing 2025 in Key West, Florida, December 11-14, where global leaders in vascular surgery, wound care, diabetic limb salvage, and regenerative therapeutics gather to present cutting-edge advancements. Hemostemix will highlig
Biotechnology, Pharmaceuticals, Health
2025-12-03 2:05 PM EST | Hemostemix Inc.
Microbiome Labs Launches DigestMate, a 2-in-1 Digestive Enzyme and Probiotic Formula
Franklinton, North Carolina--(Newsfile Corp. - December 3, 2025) - Microbiome Labs, a leader in microbiome-based solutions, today announced the launch of DigestMate™, a 2-in-1 digestive enzyme and probiotic formula. Digestive health challenges are on the rise in America, impacting millions of lives and driving demand for innovative solutions. According to recent data from the Centers for Disease Control and Prevention (CDC) and the National Institute of Diabetes and Digestive and
2025-12-03 11:44 AM EST | Microbiome Labs
BioHarvest Sciences Announces Launch of VINIA Blood Flow Hydration Product
British Columbia and Rehovot, Israel--(Newsfile Corp. - December 3, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology platform, announces the U.S. launch of VINIA Blood Flow Hydration™, the first hydration solution powered by the blood flow
Biotechnology, Pharmaceuticals, Health
2025-12-03 7:30 AM EST | BioHarvest Sciences Inc.
TempraMed Signs Exclusive Commercial Distribution Agreement with Leading Distributor to the Turkish Market
Dolfin is a well-established, diversified distributor with broad reach across healthcare, hospitals, emergency services, and consumers provides strong potential for VIVI products to gain traction Turkey is one of the highest-prevalence diabetes countries in Europe due to obesity rates, diet, urbanization, and low screening compliance One of many distribution agreements in pipeline for Europe as part of TempraMed's def
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-02 5:00 PM EST | TempraMed Technologies Ltd.
BYT Announces Normal Course Issuer Bid and Results of Its Annual General Meeting
Vancouver, British Columbia--(Newsfile Corp. - December 2, 2025) - BYT Holdings Ltd. (CSE: BYT) ("BYT" or the "Company") announces that it intends to initiate a normal course issuer bid ("NCIB") through the facilities of the Canadian Securities Exchange ("CSE") or alternative trading systems and the results from its most recent annual general meeting of shareholders held on October 16, 2025. Normal Course Issuer Bid The Board of the Company belie
Technology, Biotechnology, Construction / Building, Machinery
2025-12-02 4:54 PM EST | BYT Holdings Ltd.
PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise
Toronto, Ontario--(Newsfile Corp. - December 2, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the therapeutic potential of ketamine for neuropsychiatric disorders, today announced it has closed the previously announced sale of its Abbreviated New Drug Application (ANDA #217858) for Ketamine Hydrochloride Injection USP to a leading sterile-injectables pharmaceutical company. At closing,
Biotechnology, Pharmaceuticals
2025-12-02 9:53 AM EST | PharmaTher Holdings Ltd.
Hemostemix to Attend DFCon San Antonio and Closed its Private Placement
Calgary, Alberta--(Newsfile Corp. - December 2, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is proud to announce its participation in DFCon 2025, hosted by the American Limb Preservation Society in San Antonio, Texas - the global epicentre for innovation in diabetic foot care, vascular medicine, and limb preservation. With more than 500 delegates expected, DFCon gathers the widest spectrum of professionals shaping the future of diabetic limb salvage: podiatrists, vascular surgeo
Biotechnology, Pharmaceuticals, Health
2025-12-02 9:10 AM EST | Hemostemix Inc.
Envoy Medical Announces the Grant of Its 40th U.S. Patent
White Bear Lake, Minnesota--(Newsfile Corp. - December 2, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has received its 40th active U.S. Patent from the United States Patent and Trademark Office. The new patent further strengthens the Company's intellectual property portfolio, which includes an additional 45 issued foreign patents. U.S. Paten
Biotechnology, Healthcare and Hospitals
2025-12-02 8:00 AM EST | Envoy Medical, Inc.
BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala
Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is honored to announce that the Company and its research partners from the Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval (IUCPQ-UL) were awarded the Innovation Award from Industrial Research Cluster during the 35th annual ADRIQ
Technology, Biotechnology, Healthcare and Hospitals
2025-12-01 8:30 AM EST | BioMark Diagnostics, Inc.
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute myocarditis. Results provide clinical evidence that CardiolRx™ reduces inflammation-driven structural damage in the heart, an important cause of heart failure progression. The ARCHER data strengthen
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2025-12-01 7:27 AM EST | Cardiol Therapeutics Inc.
Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds
Encinitas, California--(Newsfile Corp. - December 1, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office issued a new patent (US-12,472,263) on additional and novel formulations of the KIO-100 family of compounds, This patent allows for additional delivery options, expanding the potential therapeutic utility of the active pharmaceutical ingredient (API) in KIO-104. This newly issued patent specifically covers a novel formulation
Biotechnology, Pharmaceuticals
2025-12-01 6:45 AM EST | Kiora Pharmaceuticals, Inc.
Aires Announces Record Q3/2025 Revenue of $7.4 Million and 61% YoY Sales Growth and Discusses Factors Related to Liquidity and Continuing Operations
Toronto, Ontario--(Newsfile Corp. - November 26, 2025) - American Aires Inc.
2025-11-26 6:00 PM EST | American Aires Inc.
TempraMed Signs Exclusive Distribution Agreement with Leading Consumer Health Distributor in Israel
Leading distributor of global companies including GSK/Haleon, Cargill, Reynolds, Paskesz Guri distributes reputable brands including Sensodyne, Aquafresh, Parodontax, Truvia, Diamond and more Strategic agreement supports TempraMed's global shift from online B2C to major pharmacy networks and B2B medical payers Distribution to over 2,500 outlets including pharmacy chains, supermarkets, HMOs and independent pha
Technology, Biotechnology, Pharmaceuticals, Health
2025-11-26 4:51 PM EST | TempraMed Technologies Ltd.
Hemostemix Starts its Roll-up of Cardiology Practices, Acquiring its First Two
Calgary, Alberta--(Newsfile Corp. - November 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), is pleased to announce a binding Letter of Intent for the acquisition of the first two cardiology practices under the Company's clinic roll-up and commercialization strategy. The practices of Dr. Roberto Manuel Fernandez-de-Castro and Dr. Hector Rosario Figueroa, two of the Dominican Republic's most respected interventional cardiologists, will be acquired by Hemostemi
Biotechnology, Pharmaceuticals, Health
2025-11-26 4:21 PM EST | Hemostemix Inc.
Sharp Therapeutics Corp. Reports Third Quarter 2025 Results and Development Update
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - November 26, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), announces the release of its condensed interim consolidated financial statements for the three and nine months ended September 30, 2025, and related management discussion and analysis. All dollar figures are in United States dollars, unless otherwise stated. Scott Sneddon, Sharp's Chief Executive Officer
2025-11-26 7:35 AM EST | Sharp Therapeutics Corp.
Optimi Health to Supply MDMA to MAPS Israel's Clinical Trial for Trauma-Related PTSD
Vancouver, British Columbia--(Newsfile Corp. - November 26, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian manufacturer of pharmaceutical-grade psychedelics, including MDMA and naturally derived psilocybin, has been selected to supply the MDMA capsules for MAPS Israel's Healing October 7th project, which includes a clinical trial for Post-Traumatic Stress Disorder (PTSD) that has received formal approval from the Israeli
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-11-26 7:00 AM EST | Optimi Health Corp.
PreveCeutical Medical and BioGene Therapeutics Announce Closing of Plan of Arrangement
Vancouver, British Columbia--(Newsfile Corp. - November 26, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") and BioGene Therapeutics Inc. ("BioGene"), are pleased to announce that, further to its News Releases of September 4, 2025, September 19, 2025, October 10, 2025, Oc
Biotechnology, Pharmaceuticals, Health
2025-11-26 7:00 AM EST | PreveCeutical Medical Inc.
MustGrow Announces Record Q3-2025 Results
Saskatoon, Saskatchewan--(Newsfi
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2025-11-25 4:00 PM EST | MustGrow Biologics Corp.
Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - November 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today the completion of enrollment in its ongoing Phase 1b clinical trial of INTASYL siRNA PH-762. In connection with completing enrollment, Phio continues to treat additional patients in the fifth co
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-25 11:30 AM EST | Phio Pharmaceuticals Corp.